Lavipharm: First Half 2023 Financial Results

Strong EBITDA increase

Peania, 21 September 2023– Lavipharm (LAVI) reports a significant increase in consolidated sales and EBITDA during the First Half of 2023. The impressive results exceed sales forecasts, as disclosed in the prospectus of the recent share capital increase, for a second consecutive year.

Please refer to the attachment for the announcement.

Please see attached.

FOR IMMEDIATE RELEASE

21 September 2023

Coca-Cola HBC AG (the “Company”)

Notification of transactions by Persons Discharging Managerial Responsibilities (“PDMRs')

The Company has been notified that the following PDMR sold ordinary shares of CHF 6.70 each in the Company on 20 September 2023.

FOR IMMEDIATE RELEASE

21 September 2023

Coca-Cola HBC AG (the “Company”)

Notification of transactions by Persons Discharging Managerial Responsibilities (“PDMRs')

The Company has been notified that the following PDMR sold ordinary shares of CHF 6.70 each in the Company on 20 September 2023.